Article
LRP1B affects lung adenocarcinoma immunotherapy efficacy via ferroptosis
2023-07-11
Abstract excerpt
<title>Abstract</title><p>Background Currently, the clinically used immune biomarkers for non-small cell lung cancer (NSCLC) are programmed death ligand 1 (PD-L1) and tumor mutation burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative. Methods We identified LRP1B as a potential bi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e595367d-0512-57b8-9f04-e9adca2cc895
- DOI
- 10.21203/rs.3.rs-3053993/v1
